The Benefit of Benralizumab Monoclonal Antibody Treatment for Severe Eosinophilic Asthma in a Case Series (Pulmonology Clinic Târgu Mureș, Romania)

Publicado en línea: 14 oct 2021

Páginas: 157 - 161

Recibido: 04 sept 2021

Aceptado: 11 sept 2021

DOI: https://doi.org/10.2478/jim-2021-0030

Palabras clave

monoclonal antibody therapy, severe eosinophilic asthma, clinical parameters, eosinophils

© 2021 Nimród László et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.